About Autoimmune Diseases
Autoimmune diseases are caused by aggravation of the immune system. Autoimmune diseases can last for months or even years. Autoimmune reactions occur when the immune system produces autoantibodies that attack and destroy healthy tissues in the body rather than infectious agents. These autoantibodies cause inflammation, pain, and organ damage. It is also known as a disease of flare-ups and remissions, and can range from mild to life-threatening in severity. No cure exists for autoimmune diseases yet. Autoimmune diseases can affect the cardiovascular system, brain, nerves, musculoskeletal system, skin, lungs, kidneys, glands, or joints. They are caused by genetic, infectious, and environmental factors. According to NIH, there are more than 80 clinically different autoimmune diseases. Some of the common types of autoimmune diseases are ankylosing spondylitis, Crohn's disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and psoriasis.
Technavio's analysts forecast the autoimmune diseases market in the US to grow at a CAGR of 6.17% over the period 2014-2019.
Covered in this Report
The report includes the present scenario and the growth prospects of the autoimmune diseases market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of autoimmune diseases.
Technavio's report, Autoimmune Diseases Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast for individual diseases as well as the overall market and pipeline landscape. The report includes a discussion of the key vendors operating in this market.
Key Vendors
• AbbVie
• Amgen
• Biogen
• F. Hoffmann-La Roche
• Janssen Pharmaceuticals
Other Prominent Vendors
• AB Science
• Acorda Therapeutics
• aTyr Pharma
• Baxter
• Celgene
• Celltrion
• Coherus BioSciences
• Daiichi Sankyo
• Eli Lilly
• GlaxoSmithKline
• HGS
• Hospira
• Idera
• Immunomedics
• ImmuPharma
• Invion
• Latona Life Sciences
• MedImmune
• Merck
• Novartis
• Opexa Therapeutics
• Principia
• Reata Pharmaceuticals
• Regeneron
• Sanofi
• Sobi
• Takeda
• Teva
• UCB
• Vaccinex
• Vitae Pharmaceuticals
Key Market Driver
• Unmet Medical Needs
• For a full, detailed list, view our report
Key Market Challenge
• High Cost of Therapy
• For a full, detailed list, view our report
Key Market Trend
• Increase in Public Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Epidemiology
06.3 Etiology
06.4 Symptoms
06.5 Diagnosis
06.5.1 Medical History
06.5.2 Laboratory examination
06.6 Disease Management
06.7 Quality of Life
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
08. Pipeline Portfolio
08.1 Pipeline Landscape: Crohn's Disease
08.2 Pipeline Landscape: Multiple Sclerosis
08.3 Pipeline Landscape: Systemic Lupus Erythematosus
08.5 Five Forces Analysis
09. Market Segmentation by Type of Diseases
09.1 Ankylosing Spondylitis
09.2 Crohn's Disease
09.3 Multiple Sclerosis
09.4 Psoriasis
09.5 Rheumatoid Arthritis
09.6 Systemic Lupus Erythematosus
10. Market Segmentation by Type of Molecules
10.1.1 Small Molecules
10.1.2 Biologics
11. Market Segmentation by Route of Administration
11.1.1 Parenteral Route
11.1.2 Oral Route
12. Ankylosing Spondylitis Market in the US
12.1 Market Size and Forecast
13. Crohn's Disease Market in the US
13.1 Market Size and Forecast
14. Multiple Sclerosis Market in the US
14.1 Market Size and Forecast
15. Rheumatoid Arthritis Market in the US
15.1 Market Size and Forecast
16. Psoriasis Market in the US
16.1 Market Size and Forecast
17. Systemic Lupus Erythematosus Market in the US
17.1 Market Size and Forecast
18. Buying Criteria
19. Market Growth Drivers
20. Drivers and their Impact
21. Market Challenges
22. Impact of Drivers and Challenges
23. Market Trends
24. Trends and their Impact
25. Vendor Landscape
25.1 Competitive Scenario
25.1.1 Key News
25.1.2 Mergers and Acquisitions
25.2 Market Share Analysis 2014
25.2.1 AbbVie
25.2.2 Janssen Pharmaceuticals
25.2.3 Biogen
25.2.4 Amgen
25.2.5 F. Hoffmann-La Roche
25.3 Other and Future Prominent Vendors
26. Key Vendor Analysis
26.1 AbbVie
26.1.1 Key Facts
26.1.2 Business Overview
26.1.3 Product Segmentation by Revenue 2013
26.1.4 Product Segmentation by Revenue 2012 and 2013
26.1.5 Sales by Geography
26.1.6 Business Strategy
26.1.7 Key Developments
26.1.8 SWOT Analysis
26.2 Amgen
26.2.1 Key Facts
26.2.2 Business Overview
26.2.3 Business Segmentation by Revenue 2013
26.2.4 Product Portfolio by Revenue 2013
26.2.5 Business Segmentation by Revenue 2012 and 2013
26.2.6 Geographical Segmentation by Revenue 2013
26.2.7 Business Strategy
26.2.8 Recent Developments
26.2.9 SWOT Analysis
26.3 Biogen
26.3.1 Key Facts
26.3.2 Business Overview
26.3.3 Business Segmentation by Revenue 2013
26.3.4 Geographical Segmentation by Revenue 2013
26.3.5 Business Strategy
26.3.6 Key Developments
26.3.7 SWOT Analysis
26.4 F. Hoffmann-La Roche
26.4.1 Key Facts
26.4.2 Business Overview
26.4.3 Business Segmentation
26.4.4 Business Segmentation by Revenue 2012 and 2013
26.4.5 Sales by Geography
26.4.6 Business Strategy
26.4.7 Key Information
26.4.8 SWOT Analysis
26.5 Janssen Pharmaceuticals
26.5.1 Key Facts
26.5.2 Business Overview
26.5.3 Recent Developments
26.5.4 SWOT Analysis
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Autoimmune Diseases Market in the US 2014-2019 (US$ million)
Exhibit 3: Segmentation of Autoimmune Diseases Market in the US by Type of Diseases
Exhibit 4: Percentage Share of Autoimmune Diseases Market Segment by Type of Disease 2014
Exhibit 5: Segmentation of Autoimmune Diseases Market in the US by Type of Molecules
Exhibit 6: Segmentation of Autoimmune Diseases Market in the US by Route of Administration
Exhibit 7: Ankylosing Spondylitis Market in the US 2014-2019 ($ millions)
Exhibit 8: Crohn's Disease Market in the US 2014-2019 ($ millions)
Exhibit 9: Multiple Sclerosis Market in the US 2014-2019 ($ millions)
Exhibit 10: Rheumatoid Arthritis Market in the US 2014-2019 ($ millions)
Exhibit 11: Psoriasis Market in the US 2014-2019 ($ millions)
Exhibit 12: Systemic Lupus Erythematosus Market in the US 2014-2019 ($ millions)
Exhibit 13: Autoimmune Diseases Market in the US 2014-2019 ($ millions)
Exhibit 14: AbbVie: Product Portfolio for Autoimmune Diseases
Exhibit 15: YoY Revenue of Humira in the US 2009-2014 ($ millions)
Exhibit 16: Janssen: Product Portfolio for Autoimmune Diseases
Exhibit 17: YoY Global Revenue of Remicade 2009-2014 ($ millions)
Exhibit 18: YoY Global Revenue of Simponi 2010-2014 ($ millions)
Exhibit 19: Biogen: Product Portfolio for Autoimmune Diseases
Exhibit 20: Biogen: Product Portfolio for Autoimmune Diseases
Exhibit 21: YoY Revenue of Tysabri in the US 2009-2014 ($ millions)
Exhibit 22: Revenue of Avonex in the US 2011-2014 ($ millions)
Exhibit 23: Region-wise Revenues of Plegridy 2014 ($ millions)
Exhibit 24: Region-wise Revenues of Tecfidera 2014 ($ millions)
Exhibit 25: Amgen: Product Portfolio for Autoimmune Diseases
Exhibit 26: Roche: Product Portfolio for Autoimmune Diseases
Exhibit 27: AbbVie Inc.: Product Segmentation by Revenue 2013
Exhibit 28: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 29: AbbVie Inc.: Sales by Geography 2013
Exhibit 30: Amgen: Business Segmentation by Revenue 2013
Exhibit 31: Amgen: Product Portfolio by Revenue 2013
Exhibit 32: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 33: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 34: Biogen: Business Segmentation by Revenue 2013
Exhibit 35: Biogen: Geographical Segmentation by Revenue 2013
Exhibit 36: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 37: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 38: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 39: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
